Cell Reports Medicine最新文献_第4页

Arun Sharma. 阿伦沙玛。

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-15 DOI: 10.1016/j.xcrm.2025.102048

Arun Sharma

引用次数: 0

Cooking methods affect advanced glycation end products and lipid profiles: A randomized cross-over study in healthy subjects. 烹饪方法影响晚期糖基化终产物和脂质谱：一项健康受试者的随机交叉研究

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-15 DOI: 10.1016/j.xcrm.2025.102091

Judith Wellens, Eva Vissers, Anaïs Dumoulin, Sien Hoekx, Julie Vanderstappen, Joke Verbeke, Roman Vangoitsenhoven, Muriel Derrien, Bram Verstockt, Marc Ferrante, Christophe Matthys, Jeroen Raes, Kristin Verbeke, Séverine Vermeire, João Sabino

{"title":"Cooking methods affect advanced glycation end products and lipid profiles: A randomized cross-over study in healthy subjects.","authors":"Judith Wellens, Eva Vissers, Anaïs Dumoulin, Sien Hoekx, Julie Vanderstappen, Joke Verbeke, Roman Vangoitsenhoven, Muriel Derrien, Bram Verstockt, Marc Ferrante, Christophe Matthys, Jeroen Raes, Kristin Verbeke, Séverine Vermeire, João Sabino","doi":"10.1016/j.xcrm.2025.102091","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102091","url":null,"abstract":"Thermal treatments used in ultra-processed foods (UPFs) lead to advanced glycation end products (AGEs). UPFs and serum AGEs are associated with cardiometabolic disease. We explore differential cooking methods as a mechanistic link between UPFs and detrimental health outcomes through a randomized cross-over cooking method trial in healthy subjects using identical ingredients and a deep profiling analysis. We show that low-AGE-generating cooking methods such as boiling and steaming decrease serum AGEs, improve lipid profiles, and increase serum protein 4E-BP1. In contrast, high-AGE-generating cooking methods such as grilling and baking increase fecal butyrate. In sum, this suggests that low-AGE-generating cooking methods should be considered in cardiovascular risk prevention. Since current dietary guidelines focus on ingredients, but not cooking methods, our results suggest that culinary techniques should be considered as an important factor in cardiometabolic preventive strategies and future dietary trial design. This study was registered at ClinicalTrials.gov (NCT06547190).","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102091"},"PeriodicalIF":11.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response. 胃食管腺癌围手术期化疗免疫治疗二期试验：M2巨噬细胞景观在预测反应中的作用。

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-15 DOI: 10.1016/j.xcrm.2025.102045

Thierry Alcindor, James Tankel, Pierre-Olivier Fiset, Sanjima Pal, Touhid Opu, Michael Strasser, Mehrnoush Dehghani, Nicholas Bertos, Dongmei Zuo, Carmen Mueller, Jonathan Cools-Lartigue, Marc Hickeson, Victoria Marcus, Sophie Camilleri-Broet, Alan Spatz, Gertruda Evaristo, Mina Farag, Giovanni Artho, Arielle Elkrief, Ramy Saleh, Swneke Bailey, Morag Park, Sui Huang, Veena Sangwan, Lorenzo Ferri

{"title":"Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response.","authors":"Thierry Alcindor, James Tankel, Pierre-Olivier Fiset, Sanjima Pal, Touhid Opu, Michael Strasser, Mehrnoush Dehghani, Nicholas Bertos, Dongmei Zuo, Carmen Mueller, Jonathan Cools-Lartigue, Marc Hickeson, Victoria Marcus, Sophie Camilleri-Broet, Alan Spatz, Gertruda Evaristo, Mina Farag, Giovanni Artho, Arielle Elkrief, Ramy Saleh, Swneke Bailey, Morag Park, Sui Huang, Veena Sangwan, Lorenzo Ferri","doi":"10.1016/j.xcrm.2025.102045","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102045","url":null,"abstract":"We present the clinical results of a phase 2 trial combining neoadjuvant docetaxel, cisplatin, 5 Flourouracil, and the PD-L1 inhibitor avelumab in locally advanced gastro-esophageal adenocarcinoma (GEA). Fifty-one patients receive neoadjuvant therapy with 50 proceeding to surgery. Grade 3-4 adverse events occur in 40%; complete/major pathological response is found in 7/50 (14%) and 9/50 (18%), with 2-year disease-free survival of 67.5%. There is no correlation between tumor regression and PD-L1 or mismatch repair (MMR) status. Multiplex immunohistochemistry and longitudinal single-cell transcriptomic profiling reveal alterations in certain innate immune cell populations, particularly noting an M2-tumor-associated macrophage (M2-TAM) proliferation in non-responding tumors. These findings describe the effective nature of this treatment regimen for GEA and reveal associated features of the inflammatory milieux associated with response to chemo-immunotherapy. The specific character of the inflammatory environment in non-responders may, in the future, help personalize treatment. This study was registered at ClinicalTrials.gov (NCT03288350).","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"6 4","pages":"102045"},"PeriodicalIF":11.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Specific macrophage RhoA targeting CRISPR-Cas9 for mitigating osteoclastogenesis-induced joint damage in inflammatory arthritis. 靶向CRISPR-Cas9的特异性巨噬细胞RhoA减轻炎性关节炎中破骨细胞发生诱导的关节损伤。

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-15 DOI: 10.1016/j.xcrm.2025.102046

Jianhai Chen, Jianwei Tan, Nannan Wang, Hui Li, Wenxiang Cheng, Jian Li, Benguo Wang, Adam C Sedgwick, Zhitong Chen, Guojun Chen, Peng Zhang, Wei Zheng, Chengbo Liu, Jingqin Chen

{"title":"Specific macrophage RhoA targeting CRISPR-Cas9 for mitigating osteoclastogenesis-induced joint damage in inflammatory arthritis.","authors":"Jianhai Chen, Jianwei Tan, Nannan Wang, Hui Li, Wenxiang Cheng, Jian Li, Benguo Wang, Adam C Sedgwick, Zhitong Chen, Guojun Chen, Peng Zhang, Wei Zheng, Chengbo Liu, Jingqin Chen","doi":"10.1016/j.xcrm.2025.102046","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102046","url":null,"abstract":"Rheumatoid arthritis (RA) is the most prevalent inflammatory arthritis with unknown etiology, characterized by synovial inflammation and articular bone erosion. Studies have highlighted that inhibiting macrophage-induced osteoclastogenesis holds promise in mitigating bone destruction. However, specifically halting this pathological cascade remains a challenge for the management of RA. Here, initially, we identify that Ras homolog gene family member A (RhoA) is a pivotal target in inducing osteoclastogenesis of macrophages. Subsequently, we develop a strategy termed specific macrophages RhoA targeting (SMART), in which phosphatidylserine (PS)-enriched macrophage membranes are engineered to deliver macrophage-specific promoter-containing CRISPR-Cas9 plasmids (SMART-Cas9), enabling targeted editing of RhoA in RA joint macrophages. Multiscale imaging techniques confirm the highly specific targeted effect of SMART-Cas9 on the macrophages of inflamed joints. SMART-Cas9 successfully reduces osteoclastogenesis by macrophages, thus mitigating bone erosion by modulating cytoskeletal dynamics and immune balance in inflammatory arthritis, representing a therapeutic avenue for RA and other inflammatory bone diseases.","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"6 4","pages":"102046"},"PeriodicalIF":11.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Priyanka Baloni.

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-15 DOI: 10.1016/j.xcrm.2025.102049

Priyanka Baloni

引用次数: 0

CD47-blocking antibody confers metabolic benefits against obesity. cd47阻断抗体对肥胖具有代谢益处。

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-15 DOI: 10.1016/j.xcrm.2025.102089

Yajuan Su, Jingyu Sun, Xiaobo Li, Feier Huang, Yunhui Kong, Zian Chen, Jingzhi Zhang, Duran Qin, Xiangyi Chen, Zhaoyue Wang, Yu Pei, Mengting Gong, Kaijiang Yang, Minglu Xu, Yu Dong, Qing He, Zhen-Ning Zhang, Zhejin Sheng, Qiaolin Deng, Hong Wang, Gaowei Wang, Ping Hu, Rongrong Le, Shaorong Gao, Weida Li

{"title":"CD47-blocking antibody confers metabolic benefits against obesity.","authors":"Yajuan Su, Jingyu Sun, Xiaobo Li, Feier Huang, Yunhui Kong, Zian Chen, Jingzhi Zhang, Duran Qin, Xiangyi Chen, Zhaoyue Wang, Yu Pei, Mengting Gong, Kaijiang Yang, Minglu Xu, Yu Dong, Qing He, Zhen-Ning Zhang, Zhejin Sheng, Qiaolin Deng, Hong Wang, Gaowei Wang, Ping Hu, Rongrong Le, Shaorong Gao, Weida Li","doi":"10.1016/j.xcrm.2025.102089","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102089","url":null,"abstract":"CD47-blocking antibody is a well-known potential antibody drug for tumor immunotherapy. However, it is unclear whether CD47-blocking antibody can protect against metabolic disorders. We report that high-fat diet (HFD)-induced obesity increases CD47 expression, while exercise downregulates it in skeletal muscle. Administration of CD47-blocking antibody in mice prevents HFD-induced weight gain and glucose intolerance, enhances exercise capacity, and improves body composition and skeletal muscle mitochondrial function. Mechanistically, the protective effects conferred by CD47-blocking antibody are mediated through activation of AMP-activated protein kinase (AMPK) in skeletal muscle. Consistently, muscle-specific CD47-knockout mice show similar metabolic improvements, indicating a direct muscle-specific role of CD47 in regulating AMPK activation in vivo. Furthermore, the CD47-blocking antibody reduces the phosphorylation of heat shock protein 90α (HSP90α) to activate AMPK in skeletal muscle. In conclusion, CD47-blocking antibody confers metabolic benefits by activating the AMPK pathway in skeletal muscle.","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102089"},"PeriodicalIF":11.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and opportunities in microRNA-based cancer therapeutics. 基于微rna的癌症治疗的挑战和机遇。

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-15 DOI: 10.1016/j.xcrm.2025.102057

Jingfang Ju

引用次数: 0

Celebrating 5 years of Cell Reports Medicine with authors: Past and future. 与作者一起庆祝《细胞报告医学》出版5周年：过去与未来。

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-15 DOI: 10.1016/j.xcrm.2025.102082

Jun Yu, Jakob Nikolas Kather, Ti-Fei Yuan, Marina Sirota

引用次数: 0

Integrated liver-secreted and plasma proteomics identify a predictive model that stratifies MASH. 综合肝分泌和血浆蛋白质组学确定了分层MASH的预测模型。

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-11 DOI: 10.1016/j.xcrm.2025.102085

William De Nardo, Olivia Lee, Yazmin Johari, Jacqueline Bayliss, Marcus Pensa, Paula M Miotto, Stacey N Keenan, Andrew Ryan, Amber Rucinski, Tessa M Svinos, Geraldine J Ooi, Wendy A Brown, William Kemp, Stuart K Roberts, Benjamin L Parker, Magdalene K Montgomery, Mark Larance, Paul R Burton, Matthew J Watt

{"title":"Integrated liver-secreted and plasma proteomics identify a predictive model that stratifies MASH.","authors":"William De Nardo, Olivia Lee, Yazmin Johari, Jacqueline Bayliss, Marcus Pensa, Paula M Miotto, Stacey N Keenan, Andrew Ryan, Amber Rucinski, Tessa M Svinos, Geraldine J Ooi, Wendy A Brown, William Kemp, Stuart K Roberts, Benjamin L Parker, Magdalene K Montgomery, Mark Larance, Paul R Burton, Matthew J Watt","doi":"10.1016/j.xcrm.2025.102085","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102085","url":null,"abstract":"Obesity is a major risk factor for metabolic-associated steatotic liver disease (MASLD), which can progress to metabolic-associated steatohepatitis (MASH). There are no validated non-invasive tests to stratify persons with obesity with a greater risk for MASH. Herein, we assess plasma and liver from 266 obese individuals spanning the MASLD spectrum. Ninety-six human livers were precision-cut, and mass spectrometry-based proteomics identifies 3,333 proteins in the liver-secretion medium, of which 107 are differentially secreted in MASH compared with no pathology. The plasma proteome is markedly remodeled in MASH but is not different between patients with steatosis and no pathology. The APASHA model, comprising plasma apolipoprotein F (APOF), proprotein convertase subtilisin/kexin type 9 (PCSK9), afamin (AFM), S100 calcium-binding protein A6 (S100A6), HbA1c, and zinc-alpha-2-glycoprotein (AZGP1), stratifies MASH (area under receiver operating characteristic [AUROC] = 0.88). Our investigations detail the evolution of liver-secreted and plasma proteins with MASLD progression, providing a rich resource defining human liver-secreted proteins and creating a predictive model to stratify patients with obesity at risk of MASH.","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102085"},"PeriodicalIF":11.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myeloperoxidase impacts vascular function by altering perivascular adipocytes' secretome and phenotype in obesity. 髓过氧化物酶通过改变肥胖患者血管周围脂肪细胞的分泌组和表型来影响血管功能。

IF 11.7 1区医学

Cell Reports Medicine Pub Date : 2025-04-10 DOI: 10.1016/j.xcrm.2025.102087

Alexander Hof, Max Landerer, Philipp Peitsmeyer, Ronja Herzog, Jens Alber, Maysam Ahdab, Felix Sebastian Nettersheim, Dennis Mehrkens, Simon Geißen, Simon Braumann, Henning Guthoff, Philipp von Stein, Harshal Nemade, Felix Simon Ruben Picard, Ramona Braun, Friedrich Felix Hoyer, Jens Claus Brüning, Alexander Pfeifer, Staffan Hildebrand, Holger Winkels, Stephan Baldus, Matti Adam, Jasper Schäkel, Martin Mollenhauer

{"title":"Myeloperoxidase impacts vascular function by altering perivascular adipocytes' secretome and phenotype in obesity.","authors":"Alexander Hof, Max Landerer, Philipp Peitsmeyer, Ronja Herzog, Jens Alber, Maysam Ahdab, Felix Sebastian Nettersheim, Dennis Mehrkens, Simon Geißen, Simon Braumann, Henning Guthoff, Philipp von Stein, Harshal Nemade, Felix Simon Ruben Picard, Ramona Braun, Friedrich Felix Hoyer, Jens Claus Brüning, Alexander Pfeifer, Staffan Hildebrand, Holger Winkels, Stephan Baldus, Matti Adam, Jasper Schäkel, Martin Mollenhauer","doi":"10.1016/j.xcrm.2025.102087","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102087","url":null,"abstract":"Obesity, a main driver of cardiovascular morbidity, contributes to endothelial dysfunction and inflammation in adipose tissues. Perivascular adipose tissue (PVAT) surrounds arteries and influences vascular function. In obesity, immune cells, including myeloperoxidase (MPO)-releasing myeloid cells, accumulate in PVAT. In this study, we show MPO levels to correlate with body weight and endothelial function in obese patients (n = 33) and mice. In addition, MPO deficiency reduces immune cell frequency, enhances PVAT beiging via soluble guanylyl cyclase β1 (sGC-β1), and increases oxygen consumption in vivo. Further, nitrotyrosine formation and inflammatory cytokine release are attenuated in obese Mpo-/- mice. Mechanistically, adiponectin (APN) secretion improves endothelial function and reduces arterial stiffness. In vitro, MPO-treated human white adipocytes show lower APN and brown adipocyte marker expression but increased inflammation. Thus, MPO impairs vascular function via PVAT inflammation and suppression of vasoprotective mediators, making it a potential therapeutic target in obesity-related cardiovascular disease.","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102087"},"PeriodicalIF":11.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0